Attrition in the pharmaceutical industry : reasons, implications, and pathways forward - Alex, Alexander A.; Harris, C. John; Smith, Dennis A. (Hoboken, New Jersey : John Wiley & Sons, 2015)
Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.
Includes index.
Description based on print version record and CIP data provided by publisher.
Keywords: Pharmaceutical industry -- Management; Pharmaceutical industry -- Capital productivity; Industrial efficiency; Drug development; Drug development; Industrial efficiency; Pharmaceutical industry -- Capital productivity; Pharmaceutical industry -- Management; MEDICAL / Pharmacology; Electronic books